Background: Policies that mandate list price disclosure in direct-to-consumer pharmaceutical advertising (DTCPA) cite price transparency among the benefits. The expectation is that price transparency will lead to changes in consumer behavior that will ultimately lower healthcare costs.
Objective: The objective of this study was to assess the impact of price transparency on perceived level of information and consumer behaviors, specifically intentions to seek treatment and intentions to comparison shop.
Methods: A nine-arm randomized experiment was conducted to expose respondents to television advertisements for prescription drugs that varied by price disclosure type (no price/control, list price only, or price plus, which disclosed the list price and typical out-of-pocket cost) and indicated condition (deep vein thrombosis/pulmonary embolism [DVT/PE], diabetes, or rheumatoid arthritis [RA]). The sample was recruited from US adult members of the nationally representative Amerispeak online panel.
Results: The sample included 2138 respondents. For ads featuring prescription drugs for DVT/PE, findings provide no evidence of an impact from price disclosure on perception of sufficient information. For ads for prescription drugs for diabetes, there was no evidence of an impact from list price only, but the price plus group was more likely than the control group to report the ad provided sufficient information (OR = 2.475). For ads for RA prescription drugs, both the list price only group (OR = 3.380) and price plus group (OR = 2.720) were more likely to report sufficient information than the control. Findings provide no evidence of an impact from price disclosure on consumer behaviors (i.e., intention to seek treatment or intention to comparison shop).
Conclusions: Mandatory DTCPA list price disclosure may not be the most effective tool for improving price transparency and affecting consumer behavior.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526226 | PMC |
| http://dx.doi.org/10.1016/j.rcsop.2022.100180 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Implementing recycling in the operating room: a single-center experience.
Surg Endosc
January 2025
Department of Medicine, Surgery and Healthcare Sciences, University of Trieste, Strada Di Fiume 447, 34149, Trieste, Italy.
Background: Climate change poses significant challenges to global health, exacerbated by healthcare systems' carbon footprint and waste generation. Surgical activities contribute to these impacts, necessitating sustainable practices to mitigate environmental harm. This study aims to assess the feasibility and effectiveness of a recycling program in reducing waste, carbon emissions, and disposal costs in the operating rooms (ORs).
View Article and Find Full Text PDFCost-effectiveness of lazertinib as first-line treatment in patients with -mutated advanced lung cancer.
Ther Adv Med Oncol
January 2025
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Shengli Road, Tainan 704, Taiwan.
Background: Lazertinib demonstrates efficacy similar to that of osimertinib in the first-line treatment of epidermal growth factor receptor ()-mutated advanced lung cancer. However, its cost-effectiveness has not yet been evaluated.
Objective: To study the cost-effectiveness of lazertinib as a first-line treatment for patients with -mutated advanced lung cancer.
Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies.
Curr Hematol Malig Rep
January 2025
Division of Myeloma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA, 91010, USA.
Purpose Of Review: Multiple myeloma is a chronic malignancy and with evolving treatment options, understanding the economic burden and cost-effectiveness of therapies is crucial for clinicians and researchers.
Recent Findings: In this, we review the recent approval of Bispecific antibodies and CAR-T for myeloma and their cost implications, including direct and indirect costs. We compare this to current regimens and provide cost comparisons in this review.
Emerging Alzheimer's disease treatment paradigms: A late-stage clinical trial review.
Alzheimers Dement (N Y)
December 2024
Introduction: Without disease-modifying interventions, Medicare and Medicaid spending on Alzheimer's disease (AD) management is expected to reach 637 billion USD annually by 2050. The recent advent of promising AD therapies after decades of a near-total failure rate in clinical trials suggests that more disease-modifying therapies are on the horizon. In this review, we assess the late-stage pipeline of disease-modifying candidates for AD and offer a novel classification of intervention candidates by treatment paradigms-groups of candidates that share an underlying biological mechanism of action and general disease target.
View Article and Find Full Text PDFCigarette smoking and symptom burden: baseline results from 9 ECOG-ACRIN cancer clinical trials.
J Pain Symptom Manage
December 2024
Wake Forest University School of Medicine, Winston-Salem, NC; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
Context: Approximately 11% of cancer survivors smoke post-diagnosis.
Objective: Understanding the relationship between smoking and perceived cancer-related symptoms may inform tobacco treatment interventions for this population.
Methods: From 2017-2021, 740 adults in 9 ECOG-ACRIN trials provided baseline data.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!